MwanzoATYR • NASDAQ
add
aTyr Pharma Inc
$ 6.03
Baada ya Saa za Kazi:(3.65%)+0.22
$ 6.25
Imefungwa: 12 Sep, 19:59:57 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 5.26
Bei za siku
$ 5.22 - $ 6.50
Bei za mwaka
$ 1.67 - $ 7.29
Thamani ya kampuni katika soko
590.86M USD
Wastani wa hisa zilizouzwa
4.19M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 4.93M | 47.49% |
Mapato halisi | -19.53M | -19.78% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.22 | 4.35% |
EBITDA | -20.15M | -17.56% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 80.35M | 2.38% |
Jumla ya mali | 101.53M | -4.16% |
Jumla ya dhima | 26.88M | 9.64% |
Jumla ya hisa | 74.66M | — |
hisa zilizosalia | 97.99M | — |
Uwiano wa bei na thamani | 6.49 | — |
Faida inayotokana na mali | -51.09% | — |
Faida inayotokana mtaji | -57.98% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -19.53M | -19.78% |
Pesa kutokana na shughuli | -13.89M | 32.06% |
Pesa kutokana na uwekezaji | 3.30M | -50.94% |
Pesa kutokana na ufadhili | 17.90M | 33.56% |
Mabadiliko halisi ya pesa taslimu | 7.30M | 2,375.39% |
Mtiririko huru wa pesa | -6.43M | 51.63% |
Kuhusu
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Ilianzishwa
1 Jan 2005
Tovuti
Wafanyakazi
61
